Biotechs ready to rock
And roll..
And roll..
Here is the portfolio approach we promised in the last article. The possible gains are such that if even just a couple make it through the next regulatory hurdle, the […]
The regulatory approval process for new drugs is Byzantine, lengthy, and unpredictable. Single stocks are, for outsiders at least (even insiders can be surprised), almost pure bets. But one can […]